- Home
- FLNC vs PVLA Comparison
FLNC vs PVLA Comparison
Compare FLNC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- PVLA
- Stock Information
- Founded
- FLNC 2018
- PVLA 2015
- Country
- FLNC United States
- PVLA United States
- Employees
- FLNC N/A
- PVLA N/A
- Industry
- FLNC Industrial Machinery/Components
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- PVLA Health Care
- Exchange
- FLNC Nasdaq
- PVLA Nasdaq
- Market Cap
- FLNC 974.7M
- PVLA 888.0M
- IPO Year
- FLNC 2021
- PVLA N/A
- Fundamental
- Price
- FLNC $15.11
- PVLA $94.04
- Analyst Decision
- FLNC Hold
- PVLA Strong Buy
- Analyst Count
- FLNC 19
- PVLA 13
- Target Price
- FLNC $10.44
- PVLA $106.23
- AVG Volume (30 Days)
- FLNC 7.4M
- PVLA 215.9K
- Earning Date
- FLNC 11-24-2025
- PVLA 11-11-2025
- Dividend Yield
- FLNC N/A
- PVLA N/A
- EPS Growth
- FLNC N/A
- PVLA N/A
- EPS
- FLNC N/A
- PVLA N/A
- Revenue
- FLNC $2,449,087,000.00
- PVLA N/A
- Revenue This Year
- FLNC N/A
- PVLA N/A
- Revenue Next Year
- FLNC $20.89
- PVLA N/A
- P/E Ratio
- FLNC N/A
- PVLA N/A
- Revenue Growth
- FLNC 14.26
- PVLA N/A
- 52 Week Low
- FLNC $3.46
- PVLA $11.17
- 52 Week High
- FLNC $24.00
- PVLA $101.94
- Technical
- Relative Strength Index (RSI)
- FLNC 42.47
- PVLA 72.57
- Support Level
- FLNC $14.58
- PVLA $90.00
- Resistance Level
- FLNC $18.28
- PVLA $101.94
- Average True Range (ATR)
- FLNC 2.25
- PVLA 6.45
- MACD
- FLNC -0.75
- PVLA 1.64
- Stochastic Oscillator
- FLNC 9.06
- PVLA 98.32
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.